Upload
truongnguyet
View
213
Download
0
Embed Size (px)
Citation preview
INSTITUTO BUTANTAN
800.000 m21901Established to produce serum against the bubonic plague
Vital Brazil, first director, investigated antivenoms against snake
bites
INSTITUTO BUTANTAN
• 23 scientific labs
- Scientific Development Division [16 Labs]
- Biotechnology Center [3 labs]
- Applied Toxinology Special Lab – LETA [4 labs]
• Hospital Vital Brazil [10 beds]
• Central Animal Facility
• 180 PhD researchers
• 500 graduated students
• more than 200 published articles
• 4.274 citations in 2013
• Programs of Scientific Initiation
• Training Programs
• University Extension Courses
• Graduated studies in Toxinology
• MBA in Innovation
• Graduated inter-unities studies in Biotechnology [University
of São Paulo, Institute for Technological Research, Instituto Butantan]
Source: Instituto Butantan; ISI web of science
INSTITUTO BUTANTAN
7 plants
• Anaerobic vaccines
- Tetanus and Botulism
• Bacterial Purification Center
• Aerobic Vaccines
- Diphtheria and Pertussis
• Hepatitis
• Influenza
• Rabies
• Serums
1 Formulation and Filling Center
6 pilot plants
• Dengue
• Rotavirus
• Recombinant BCG
• Monoclonal antibodies
• Influenza - H5N1
• Blood products
PORTFOLIO OF SERUM
5 snake antivenoms Diphtheria
antitoxin
Spider antivenom
Caterpillar
antivenom
Tetanus antitoxin
Botulism E antitoxin
Rabies
immunoglobulin
Botulism AB
antitoxin
Scorpion
antivenom
13 immunoglobulins 400,000 vials/year
PORTFOLIO OF VACCINES
DTP Diphtheria-Tetanus-Pertussis
(celular)
DT
Diphtheria-Tetanus
(for children)
dT
Diphtheria-Tetanus
(for adults)
Rabies
Hepatitis B
Influenza
6 vaccines of the national calendar 150 million doses per year
TTO Instituto Butantan’s TTO was
established in 2012.
Classification Number
vaccine 12
serum 3
immunotherapy 3
coagulant 2
analgesic 2
peptide 2
tissue regeneration 2
anti cancer 1
antibodies 2
other* 11
total 40
Lopap – 4 patentsBiolab
Amblyomin-X – 1 patentUnião Química Ind. Farmacêutica
Sílica (SBA-15) – 1 patent
Cristália
Pertussis low – 1 patent
* other includes: proteins from Leptospira, spiderproteins, DNA of S. mansoni, crotamine, kit andcomposition, recombinant protein for diagnosis, etc.
TETRAVALENT VACCINE: DTP+PNEUMONIAE
• Priority application number: PI1003753-5;
• Priority data: 28 september 2010;
• Title: Synergistic immunogenic compositions based on protein antigenscombined with pertussis cell antigen and inactivated toxins;
• Geographical coverage: Brazil and United States of America;
• Abstract: Pneumococcal surface protein A (PSPA) is an antigen for thecomposition of protein-based vaccines against Streptococcus pneumoniae. Thesuccessfully addition of pneumococcal protein in to pertussis whole cell vaccinewas demonstrated. We propose a tetravalent vaccine DTP + PSPA. We aredeveloping pnemococcal antigens for the conjugation.
• More info: [email protected]
BCG RECOMBIANT VACCINE
• Priority application number: BR1020120037904;
• Priority data: 17 february 2012;
• Title: Recombinant mycobacterium bovis bacillus calmette guerin (BCG)strain, immunogenic composition and use;
• Geographical coverage: Brazil, United States of America, Europe,China, India and South Africa;
• Abstract: Production of a recombinant vaccine for prevention againsttuberculosis and infections caused by Mycobacterium. Results havedemonstrated that the protection is enhanced three times. We have alreadydone concept proofs.
• More info: [email protected]
ANTI-DIGOXIN MONOCLONAL ANTIBODY
• Priority application number: BR1020120114933;
• Priority data: 15 june 2012;
• Title: Method for producing and obtaining variable domains of anti-digoxinmonoclonal antibody FAB fragment using the molecular biology cloningtechnique;
• Geographical coverage: Brazil and PCT
• Abstract:Monoclonal antibody produced by phage display technology thatworks as an antidote and is used in the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Thisantibody is not produced in animals. It is in scaling up process of development.
• More info: [email protected]
THANK YOU!Luciana Akissue de C. Teixeira
Coordinator of Instituto Butantan’s TTO55 (11) 2627 9669